Dr. Danil Victor Makarov, MD, MHS

Dr. Makarov practices at NYU Faculty Group Practice in Brooklyn, New York.

Dr. Makarov's NPI, 1730226366, was assigned on January 31, 2007. Dr. Makarov graduated from Johns Hopkins University School of Medicine in 2002. Dr. Makarov holds Maryland license NONE.

Dr. Makarov's primary practice is NYU Faculty Group Practice, at 1220 Ave P, Brooklyn, NY 11229 in Kings County. The practice phone is (877) 648-2964.

Dr. Makarov's primary practice is NYU Faculty Group Practice in Brooklyn, New York. Dr. Makarov is also affiliated with Tisch Hospital. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Makarov to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Makarov practices, 2 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Makarov's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Makarov is licensed in Maryland.

CMS data shows 303 Medicare services from Dr. Makarov across 4 procedure codes in 2024, for 137 Medicare patients. Medicare paid $23,414 for them. Every service was in an office.

CMS counts 137 Medicare patients who saw Dr. Makarov in 2024. The largest group is 65 to 74, with 52 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 75% are also on Medicaid. Their average risk score is 1.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Makarov's median patient age at 67, with 30% women.

In 2024, Dr. Makarov wrote 1,022 Medicare Part D claims for 200 patients. 91% of them were for generic drugs. CMS names the drug for 906 of them, across 10 drugs with 11 or more claims each, at $59,932 in total drug cost. In 2023, CMS named 853 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Makarov for performance year 2024, reported as part of a group. Dr. Makarov accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Makarov as offering telehealth.

Dmand AI links 121 papers to Dr. Makarov, published from 2010 to 2025. 2021 was the busiest year, with 15. The most frequent topics are Prostatic Neoplasms, Prostate-Specific Antigen and Practice Patterns, Physicians'. Dr. Makarov has published most often in Urology. Dr. Makarov's most frequent co-authors are Scott Eliot Sherman, MD, Daniel Jacob Becker, MD and John Thomas Leppert, MD.

Dmand AI links Dr. Makarov to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Prostatic Neoplasms and Prostatic Diseases.

CMS Open Payments shows 19 general payments to Dr. Makarov from 11 drug and device companies from 2017 to 2025. Travel and lodging make up the largest share, 52% of the total. Sanofi and Genzyme US Companies paid the most, $850.

Dr. Makarov graduated from Johns Hopkins University School of Medicine in 2002.